Golimumab — Drug Intelligence | 14 EU Trials

Filter these 14 trials by condition, phase, country and more.

Open in Search →

14 Registered trials

4 Recruiting

6 Completed trials

13 Sponsors

21 Countries

Phase III

Phase II

Phase III/IV

Phase IV

Phase III: 3 Phase II: 2 Phase III/IV: 2 Phase IV: 7

Indications tested

Juvenile idiopathic arthritis 1 Rheumatoid arthritis 1 Psoriatic arthropathy 1 Peripheral spondyloarthritis 1

Sponsors using this IMP

Janssen - Cilag International 3 Aalborg University Hospital 1 Centre Hospitalier Universitaire Amiens Picardie 1 Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) 1 Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz 1 IRCCS Istituto Giannina Gaslini 1 Janssen Biologics B.V. 1 Les Hopitaux Universitaires De Strasbourg 1 Oslo Universitetssykehus HF 1 Oslo University Hospital HF 1 Sint Maartenskliniek Stichting 1 Universitaetsklinikum Heidelberg AöR 1

All trials

14 total

IMPACT OF ANTI-TNF, VEDOLIZUMAB AND TOFACITINIB ON AORTIC STIFFNESS, CAROTID INTIMA-MEDIA THICKNESS AND CARDIOVASCULAR RISK OF PATIENTS WIT… Pending

2024-517314-15-00 Phase III/IV 1 country Centre Hospitalier Universitaire Amiens Picardie
The OASE study Pending

2026-525221-21-01 Phase IV 1 country Aalborg University Hospital
Discontinuation of disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis patients also using TNF inhibitors Pending

2026-525316-33-00 Phase IV 1 country Sint Maartenskliniek Stichting
The Treat-JIA trial Pending

2026-525611-13-00 Phase IV 1 country Oslo Universitetssykehus HF
Toward personalized medicine to guide drug withdrawal in children with juvenile idiopathic arthritis in clinical remission: a randomized cli… Recruiting

2024-514732-24-00 Phase IV 7 countries IRCCS Istituto Giannina Gaslini
MOVE-JIA trial Recruiting

2024-513017-12-00 Phase IV 1 country Oslo University Hospital HF
An unblinded clinical Trial with random assignment to Treatment Groups in adult patients with psoriatic arthrits to evaluate how far immunos… Recruiting

2023-508251-39-00 Phase III 2 countries Universitaetsklinikum Erlangen AöR
RANDOMIZED CONTROLLED CLINICAL TRIAL EVALUATING METHOTREXATE OR LEFLUNOMIDE + TARGETED THERAPY VERSUS METHOTREXATE OR LEFLUNOMIDE + SULFASAL… Recruiting

2024-516704-41-00 Phase III/IV 1 country Les Hopitaux Universitaires De Strasbourg
Comparing the effectiveness of our tailor-made management approach with routine care from a clinical, patient's as well as an economic point… Ended

2024-511530-12-01 Phase IV 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn's Disease Ended

2023-504741-32-00 Phase II 19 countries Janssen - Cilag International
Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colit… Ended

2023-504743-13-00 Phase II 20 countries Janssen - Cilag International
SPondyloArthritis: inducing drug-free Remission by early TNF-Alpha bloCkade Under guidance of Single cell RNA sequencing and epigenetic prof… Ended

2023-510085-27-00 Phase III 1 country Universitair Ziekenhuis Gent
Effect of Tofacitinib on coagulation and platelet function, and its role in thromboembolic events Ended

2024-518434-83-01 Phase IV 1 country Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Princesa
A Study of the Efficacy and Safety of Golimumab in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis Ended

2023-507142-83-00 Phase III 3 countries Janssen - Cilag International; Janssen Biologics B.V.

Showing 1–14 of 14 trials

← All drugs A–Z